Adebrelimab

阿得贝利单抗

Report date: 2026/05/20 20:02:01

Base Information

Drug NameAdebrelimab
Drug Alias NameAdelbelimumabAdelbelimabAdebelizumabAddebelizumabAdebellizumab +[14] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed death-ligand 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursOvarian Diseases +[28] 
Global Approved IndicationsSmall Cell Lung Carcinoma
Approved Indications in ChinaSmall Cell Lung Carcinoma
Original Approved Country/TerritoryMainland China
Original Approved Date2023/02/28
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co LtdAtridia Pty Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesFujian Cancer HospitalCancer Hospital Of Chinese Academy Of Medical SciencesShanghai Suncadia Medicine Co Ltd +[10] 
Inactive CompaniesHuazhong University Of Science And TechnologySichuan UniversityAtridia Pty Ltd
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursOvarian Diseases +[27] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBank